STELLA NKWOCHA: Open Payments
NPI 1487296828 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,327 in 49 payments from 12 companies in 2025. Trend: 2023 $1,450 · 2024 $1,520 · 2025 $1,327
Food & beverage: $1,327
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 7 | $280 |
| Supernus Pharmaceuticals, Inc. | 8 | $220 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $195 |
| Alkermes, Inc. | 7 | $152 |
| Otsuka America Pharmaceutical, Inc. | 4 | $104 |
| Indivior Inc. | 3 | $87 |
| E.R. Squibb & Sons, L.L.C. | 4 | $85 |
| Teva Pharmaceuticals USA, Inc. | 3 | $72 |
| Lundbeck LLC | 3 | $65 |
| ABBVIE INC. | 2 | $36 |
Products named: INGREZZA, Qelbree, CAPLYTA, SUBLOCADE, COBENFY, ARISTADA, ABILIFY MAINTENA, UZEDY.
Industry payments across MD — which companies pay providers there.
